A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab

The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total patho...

全面介紹

書目詳細資料

Principais autores:	Charlie Yang, Raida Khwaja, Patricia Tang, Nancy Nixon, Karen King, Sasha Lupichuk
格式:	Artigo
語言:	Inglês
出版:	MDPI AG 2022-06-01
叢編:	Current Oncology
主題:	trastuzumab biosimilar MYL-1401O HER2+ breast cancer early stage
在線閱讀:	https://www.mdpi.com/1718-7729/29/6/337
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!